Your browser is no longer supported. Please, upgrade your browser.
CBMG Cellular Biomedicine Group, Inc. monthly Stock Chart
CBMG [NASD]
Cellular Biomedicine Group, Inc.
Index- P/E- EPS (ttm)-2.83 Insider Own45.09% Shs Outstand19.43M Perf Week1.91%
Market Cap364.84M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float8.97M Perf Month2.63%
Income-54.80M PEG- EPS next Q- Inst Own34.20% Short Float4.22% Perf Quarter-0.48%
Sales0.30M P/S1216.12 EPS this Y-19.90% Inst Trans21.33% Short Ratio5.82 Perf Half Y42.42%
Book/sh0.89 P/B21.01 EPS next Y- ROA-61.90% Target Price19.00 Perf Year2.69%
Cash/sh1.33 P/C14.03 EPS next 5Y- ROE-145.40% 52W Range11.48 - 19.50 Perf YTD15.15%
Dividend- P/FCF- EPS past 5Y-13.00% ROI-72.80% 52W High-4.10% Beta1.41
Dividend %- Quick Ratio0.50 Sales past 5Y-9.60% Gross Margin80.80% 52W Low62.89% ATR0.34
Employees217 Current Ratio0.50 Sales Q/Q- Oper. Margin- RSI (14)65.99 Volatility1.53% 2.08%
OptionableYes Debt/Eq2.77 EPS Q/Q-6.40% Profit Margin- Rel Volume0.23 Prev Close18.64
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume65.09K Price18.70
Recom3.00 SMA204.75% SMA502.89% SMA20016.50% Volume14,842 Change0.32%
Aug-13-20Downgrade Robert W. Baird Outperform → Neutral $19
Jul-13-20Upgrade Robert W. Baird Neutral → Outperform
Mar-05-20Downgrade BTIG Research Buy → Neutral
Nov-12-19Downgrade Robert W. Baird Outperform → Neutral $26 → $19
Sep-17-19Initiated BTIG Research Buy $19
Jun-25-19Initiated Cantor Fitzgerald Overweight $27
Feb-07-19Initiated Robert W. Baird Outperform
Mar-08-18Initiated B. Riley FBR, Inc. Buy $32
Feb-01-18Downgrade Maxim Group Buy → Hold
Nov-29-16Reiterated Maxim Group Buy $16 → $18
Sep-22-16Initiated Maxim Group Buy $16
Nov-27-20 04:12AM  
Nov-25-20 10:28PM  
Nov-24-20 03:50PM  
Nov-23-20 08:31PM  
Nov-18-20 08:00AM  
Nov-16-20 06:49PM  
Nov-13-20 10:37PM  
08:00AM  
Nov-12-20 12:25PM  
Nov-09-20 05:24PM  
Nov-07-20 02:40PM  
Nov-06-20 10:20PM  
09:45AM  
08:01AM  
Nov-05-20 03:28PM  
Nov-04-20 11:00AM  
Nov-03-20 01:15PM  
Oct-31-20 07:45PM  
Oct-30-20 09:44PM  
Oct-29-20 10:35AM  
Oct-28-20 05:00PM  
Oct-27-20 10:15AM  
Oct-26-20 05:17PM  
Oct-24-20 02:10PM  
Oct-23-20 08:00PM  
06:59PM  
04:44PM  
Oct-21-20 10:20PM  
04:17PM  
Oct-20-20 03:12PM  
Oct-19-20 03:14PM  
Oct-17-20 02:05PM  
Oct-16-20 09:51PM  
09:00PM  
Oct-15-20 12:07PM  
Oct-14-20 07:00PM  
01:14PM  
Oct-13-20 08:20PM  
07:00AM  
Oct-12-20 06:45PM  
08:00AM  
Oct-09-20 11:42AM  
10:46AM  
08:01AM  
Oct-06-20 11:10AM  
Oct-05-20 10:56PM  
10:30PM  
Oct-02-20 08:01PM  
Sep-26-20 06:25AM  
Sep-25-20 09:00PM  
04:55PM  
Sep-24-20 03:55PM  
10:48AM  
Sep-23-20 11:50PM  
01:35PM  
Sep-22-20 06:45PM  
03:00PM  
02:07PM  
Sep-21-20 03:10PM  
Sep-20-20 08:00PM  
Sep-17-20 02:50PM  
Sep-16-20 01:17PM  
Sep-15-20 01:33PM  
09:35AM  
Sep-12-20 11:00AM  
Sep-10-20 09:36PM  
Sep-03-20 01:10AM  
Sep-02-20 08:00PM  
09:35AM  
Sep-01-20 11:17PM  
07:39PM  
07:31PM  
Aug-27-20 04:30PM  
Aug-26-20 04:50PM  
09:50AM  
09:00AM  
Aug-25-20 06:20PM  
10:35AM  
08:03AM  
Aug-24-20 06:56PM  
06:30PM  
Aug-22-20 07:35AM  
Aug-20-20 03:21PM  
10:15AM  
Aug-19-20 05:50PM  
04:30PM  
Aug-18-20 03:20PM  
02:00PM  
Aug-17-20 06:45PM  
05:25PM  
11:00AM  
Aug-14-20 10:35PM  
08:05PM  
03:37PM  
08:30AM  
02:30AM  
Aug-13-20 06:55PM  
03:25PM  
03:20PM  
08:18AM  
Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.